The scope of the proposed project is to formalize our understanding on the antiviral capacity of our natural bioproducts by testing them against SARS-CoV-2 and other enveloped viruses, such as influenza. This development will enable us to then propose our Dispersa technology in an antiviral capacity, not only for sanitation of skin and surfaces - but also an added application of antiviral coating for medical equipment and infrastructure. We hope to contribute to COVID-19 efforts by leveraging our innovation to provide natural solutions to society during this global crisis.